RECOVERY (Tocilizumab)
2021
Tocilizumab in COVID-19
In 4,116 hospitalised hypoxic patients with COVID-19 and inflammation, tocilizumab reduced 28-day mortality compared with usual care.
Result
Efficacy: 28-day all-cause mortalityRR 0.85
Below 1 favours tocilizumab, above 1 favours usual care.
- Absolute difference
- 4 points
The absolute difference is derived from the event rates.
Also reported: Combined with dexamethasone in most patients.
- Subtopic
- IL-6 antagonists
- Design
- Adaptive platform RCT, UK
- Relevance
- Important: one of several pillars.
- Source
- RECOVERY Collaborative Group. Lancet. 2021;397(10285):1637-1645.doi 10.1016/S0140-6736(21)00676-0
Discussion & critique
Confirmed REMAP-CAP signal; add tocilizumab in rapidly worsening, CRP-high patients on steroids.